CAR-T cells against tumor-specific antigens (TSA), including mesothelin (MSLN) and glypican 3 (GPC3) are being actively tested for treating non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma, respectively [7–19]. The gene discussed is MSLN; the disease is hepatocellular carcinoma.